DUBLIN, Oct. 14,
2022 /PRNewswire/ -- Medtronic plc (NYSE:MDT), a
global leader in healthcare technology, today announced the company
will host a webcast to provide an update on its Medtronic Coronary
and Renal Denervation business during the American Heart
Association annual scientific sessions (AHA 2022) on Monday, November 7, 2022, at 5 p.m. CST. The webcast will feature remarks from
Medtronic Coronary and Renal Denervation management, including
comments on the 6-month results from the SPYRAL HTN-ON MED
Randomized Trial (ON MED). These data will be presented as part of
a late-breaking science session at AHA 2022 on November 7, with the ON MED data presentation
scheduled to begin at approximately 3:38
p.m. CST. The company intends to issue a press release
discussing the ON MED results on November
7 at the start of the ON MED late-breaking science session
presentation.
The live audio webcast of the investor and analyst briefing can
be accessed by clicking on the Investor Events link
at http://investorrelations.medtronic.com on November 7, 2022. Within 24 hours of the webcast,
a replay will be available on the same webpage. The investor and
analyst briefing is not part of the official AHA 2022 program.
About Medtronic
Bold thinking. Bolder actions. We are
Medtronic. Medtronic plc, headquartered in Dublin, Ireland, is the leading global
healthcare technology company that boldly attacks the most
challenging health problems facing humanity by searching out and
finding solutions. Our Mission — to alleviate pain, restore health,
and extend life — unites a global team of 95,000+ passionate people
across 150 countries. Our technologies and therapies treat 70
health conditions and include cardiac devices, surgical robotics,
insulin pumps, surgical tools, patient monitoring systems, and
more. Powered by our diverse knowledge, insatiable curiosity, and
desire to help all those who need it, we deliver innovative
technologies that transform the lives of two people every second,
every hour, every day. Expect more from us as we empower
insight-driven care, experiences that put people first, and better
outcomes for our world. In everything we do, we are engineering the
extraordinary. For more information on Medtronic (NYSE:MDT), visit
www.Medtronic.com and follow @Medtronic on Twitter and
LinkedIn.
Any forward-looking statements are subject to risks and
uncertainties such as those described in Medtronic's periodic
reports on file with the Securities and Exchange Commission. Actual
results may differ materially from anticipated results.
Contacts:
|
|
|
|
Erika Winkels
|
Ryan
Weispfenning
|
Public Relations
|
Investor
Relations
|
+1-763-526-8478
|
+1-763-505-4626
|
View original content to download
multimedia:https://www.prnewswire.com/news-releases/medtronic-to-webcast-renal-denervation-investor--analyst-briefing-on-november-7-301649793.html
SOURCE Medtronic plc